Paris

• A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient … Ended recruitment
  2024-517622-25-00 5 2013-12-06 Patients with localized prostate cancer and high-risk features of rela
• Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended recruitment
  2024-516198-61-00 5 2013-06-05 Patients with high risk of relapse, ER+ and HER2- primary non-metastat
• Phase I/II Follow-up Study of SAR422459 in Patients with Stargardt’s Macular Degeneration Ended recruitment
  2024-513501-31-00 4 2013-05-30 Congenital, hereditary and neonatal diseases
• Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco … Ended recruitment
  2024-516996-34-00 5 2012-04-12 oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
• Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients Ended recruitment
  2024-515171-35-00 5 2011-07-06 Prostatic adenocarnicoma with high risk of recurrence
• RB SFCE 2009 : Adjuvant treatment in extensive unilateral retinoblastoma primary enucleated Ended recruitment
  2024-514844-10-00 4 2010-03-18 Retinoblastoma
• Long-Term Follow-up of Subjects With Transfusion-Dependant β-Thalassemia Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic St … Ended recruitment
  2024-513905-29-00 5 2008-10-16 Beta-thalassaemia
• Treatment protocol for osteosarcomas in children, adolescents and adults including a randomized trial and biological studies Ended recruitment
  2024-514756-32-00 5 2007-03-19 High grade osteosarcoma
• Neoadjuvant pembrolizumab with a watch-and-wait strategy for patients with mismatch repair-deficient or microsatellite instability-high (dMM … Halted
  2023-509322-22-00 4 2025-11-26 localized colon cancer
• A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomiza … Halted
  2024-514538-19-00 5 2025-11-26 Mastocytosis
• Study of CC-97540 (BMS-986353), CD19-CAR T Cells, in Participants with Active SLE Despite Immunosuppressants (Breakfree-SLE) Halted
  2024-519278-37-00 4 2025-10-22 Lupus Nephritis
• IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficac … Halted
  2024-517254-99-00 4 2025-09-16 The patients enrolled in IMMUNORARE will be adult patients with 5 rar
• Public title :A Phase 1b/2a trial to evaluate Invobenitug also known as Procizumab (PCZ; AK1967) in critical cardiovascular care. Halted
  2024-518450-16-00 9 2025-06-13 Cardiogenic shock due to Acute Coronary Syndrome, cardiogenic shock of
• Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted
  2024-516687-28-00 5 2025-06-06 Patients with GPA and inadequate response to standard of care therapy
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-6404 … Halted
  2023-505096-68-00 4 2025-01-14 Preclinical Alzheimer’s Disease
• Study of Taxane-Platinum followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma … Halted
  2023-510559-41-00 4 2025-01-02 Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
• A 24-week, multicenter, randomized, double blind, placebo-controlled, dose-range finding phase II study to compare efficacy and safety of or … Halted
  2024-515193-27-00 4 2024-09-19 Mast cell activation syndrome
• A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS Halted
  2023-507874-42-00 9 2024-08-27 Multiple sclerosis
• A trial to understand if AZD0486 is safe and helps in people with Relapsed or Refractory B-cell acute lymphoblastic leukemia (B-ALL) Halted
  2023-505840-20-00 9 2024-08-16 B-Cell Acute Lymphoblastic Leukaemia
• A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas Halted
  2022-502137-26-00 1 2024-05-03 B-cell Non-Hodgkins Lymphoma (B-NHL)
• A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1) Halted
  2023-503823-24-01 3 2024-04-15 Systemic Sclerosis
• A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulator … Halted
  2024-512626-28-00 5 2024-03-28 Duchenne Muscular Dystrophy
• A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine … Halted
  2023-505829-14-00 5 2023-12-22 First recurrence glioblastoma
• Study to assess the safety and expression of RO7494222 (SRP-9001) in participants under the age of 4 with Duchenne muscular dystrophy Halted
  2023-509901-57-00 4 2023-10-26 Duchenne Muscular Dystrophy

Showing 1,825–1,848 of 2,286 trials